Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma
Phase 2
- Conditions
- Melanoma
- Interventions
- Radiation: Stereotactic Ablative Radiosurgery (SART)
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2016-02-01
- Lead Sponsor
- Wolfram Samlowski
- Target Recruit Count
- 50
- Registration Number
- NCT01565837
- Locations
- 🇺🇸
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers
Completed
- Conditions
- Melanoma
- First Posted Date
- 2012-02-08
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Wolfram Samlowski
- Target Recruit Count
- 150
- Registration Number
- NCT01528774
- Locations
- 🇺🇸
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
News
No news found